Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes.
The effect of chlorothiazide on the pharmacokinetics of lithium in both plasma and RBCs was studied in normal adult males. This was accomplished by administering single, 300 mg. doses of lithium carbonate alone and concurrently with chlorothiazide (0.5 grams/day for one week). Thiazide administration resulted in increases in plasma and RBC concentrations of 26.2 and 25.4%, respectively, as well as a 26.5% decrease in renal lithium clearance. The data were analyzed in terms of a two compartment pharmacokinetic model as previously reported (8). The results of this analysis showed that the change in renal lithium clearance could be accounted for by a 24.1% reduction in the value of ke, the excretion rate constant. It was also shown that changes in plasma lithium concentration during chronic lithium therapy would be expected to increase by 25-30% when chlorothiazide therapy is employed. The model also predicts that changes in RBC concentrations would parallel those occurring in plasma and thus no change in the RBC/plasma lithium ratio would be expected.
D000328:Adult; D002740:Chlorothiazide / Q000494:pharmacology* / Q000652:urine; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008094:Lithium / Q000097:blood*; D008297:Male; D008954:Models, Biological
D002740:Chlorothiazide; D008094:Lithium